<DOC>
	<DOC>NCT00841568</DOC>
	<brief_summary>Investigation into the long-term safety and efficacy of OPC-41061 in repeated oral administrations at doses of 15 mg twice daily in patients with ADPKD who completed the preceding dose-finding study (156-04-001).</brief_summary>
	<brief_title>A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]</brief_title>
	<detailed_description>Investigation into the long-term safety and efficacy of OPC-41061 in repeated oral administrations at doses of 15 mg twice daily in patients with ADPKD who completed the preceding dose-finding study (156-04-001).</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Patients who completed 5day repeated administrations and the followup observation in the preceding study (15604001) Patients in whom the safety of repeated administration was confirmed based on the investigator's reports from the preceding study (15604001) Patients with serum creatinine concentration of 2.5 mg/dL or higher at the screening examination Patients with any of the following complications Uncontrolled hypertension Serious cardiovascular disease (eg. heart failure) or hepatic disease (eg. cirrhosis)" Patients with any of the following complications or history thereof Clinically significant drug allergies (anaphylaxis) or hypersensitivity (especially, hypersensitivity to benzazepine derivatives or suspected hypersensitivity thereto) Inability to personally give consent due to a mental disease " Patients with SBP (in sitting position) &lt;90 mm Hg (at screening examination) Patients with history of massive bleeding or bleeding tendency Patients with a history of drug or alcohol abuse within 6 months prior to the screening examination Pregnant women, lactating women, or women who may become or plan to become pregnant Patients who received any investigational drug other than OPC41061 within 30 days prior to commencement of administration of OPC41061 Any patient who, in the opinion of the principle investigator or attending investigators, should not participate in the study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>ADPKD</keyword>
	<keyword>Tolvaptan</keyword>
</DOC>